...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomolecules & therapeutics >Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling
【24h】

Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling

机译：溶血磷脂酸信号世界中有望的药理方向

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lysophosphatidic acid (LPA) is a signaling lipid that binds to six known lysophosphatidic acid receptors (LPARs), named LPA(1)-LPA(6). These receptors initiate signaling cascades relevant to development, maintenance, and healing processes throughout the body. The diversity and specificity of LPA signaling, especially in relation to cancer and autoimmune disorders, makes LPA receptor modulation an attractive target for drug development. Several LPAR-specific analogues and small molecules have been synthesized and are efficacious in attenuating pathology in disease models. To date, at least three compounds have passed phase I and phase II clinical trials for idiopathic pulmonary fibrosis and systemic sclerosis. This review focuses on the promising therapeutic directions emerging in LPA signaling toward ameliorating several diseases, including cancer, fibrosis, arthritis, hydrocephalus, and traumatic injury.
机译：溶血磷脂酸（LPA）是一种信号脂质，与六个已知的溶血磷脂酸受体（LPAR）结合，称为LPA（1）-LPA（6）。这些受体启动与整个身体的发育，维持和愈合过程相关的信号级联。 LPA信号的多样性和特异性，特别是与癌症和自身免疫性疾病有关的信号，使LPA受体调节成为药物开发的有吸引力的目标。已经合成了几种LPAR特异性类似物和小分子，并且在减轻疾病模型中的病理学方面有效。迄今为止，针对特发性肺纤维化和全身性硬化症，至少有三种化合物已通过I和II期临床试验。这篇综述着重于LPA信号中出现的有希望的治疗方向，以改善几种疾病，包括癌症，纤维化，关节炎，脑积水和创伤性损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号